Itopride in Functional Dyspepsia:a Dose Finding Study

• Status: Completed
• Trial end date: 2002-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to determine the efficacy and optimal dose of the prokinetic itopride for the treatment of patients with functional dyspepsia.

The study will test in patients with functional dyspepsia the hypothesis that itopride is superior to placebo with regard to the improvement of symptoms.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal Adelaide Hospital
• Collaborators: Knoll Pharmaceuticals, Germany (now Abbott); University Hospital, Essen

Criteria

Inclusion Criteria:

Diagnosis of functional dyspepsia (Rome criteria) -

Exclusion Criteria:

structural or biochemical abnormalities explaining the symptoms, concomitant symptoms of gastroesophageal reflux disease or irritable bowel syndrome dominating the clinical picture

-